FCS Trial Navigator

Select Clinic:
Select Cancer Type:
Select Line of Therapy:
Select Trial Status:
Search Protocol Info:
ProtocolTitle
391101
RM 269
A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF BAX69 IN SUBJECTS WITH MALIGNANT SOLID TUMORS
59R5-003
LUN 244
A Phase 1b/2 Study of OMP-59R5 in Combination with Etoposide and Platinum Therapy in Subjects with Untreated Extensive Stage Small Cell Lung Cancer (a ...
ABI-007-MBC-001
BRE 223
Phase 2/3 Open-Label, Randomized Study of Weekly nab-Paclitaxel with Gemcitabine or Carboplatin Compared to Gemcitabine/Carboplatin as First Line Trea ...
ABI-007-NSCL-003
LUN 263
Phase 3, Randomized, Open-Label, Crossover Study to Evaluate Abraxane as Maintenance Treatment after Induction with Abraxane plus Carboplatin in Subje ...
AG221-C-001
HR 36
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-2 ...
BO25114
GI 185
Double-Blind, Placebo-Controlled, Randomized Phase 3 Study of Pertuzumab in Combination with Trastuzumab and Chemotherapy in Her2-Positive Metastatic ...
BRE 200
BRE 200
Phase II Study of Cabazitaxel plus Lapatinib as Therapy for Her2-Positive Metastatic Breast Cancer Patients with Intracranial Metastases
BRE 212
BRE 212
A Phase II Open Label Study of Everolimus in Combination with Anti-estrogen Therapy in Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
BRE 233
BRE 233
Randomized, Multicenter, Open-Label, Phase III Trial Comparing Trastuzumab plus Pertuzumab plus a Taxane Following Anthracyclines versus Trastuzumab E ...
BRE 240
BRE 240
Phase 2 Open-Label Study to Assess the Efficacy and Safety of Enzalutamide with Trastuzumab in Subjects with HER2+ AR+ Metastatic or Locally Advanced ...
BRE 250
BRE 250
A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses ...
BVD-523-01
RM 286
PHASE I DOSE-ESCALATION, SAFETY, PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF BVD-523 IN PATIENTS WITH ADVANCED MALIGNANCIES
C16014
MM 55
Phase 3, Randomized, Double-Blind, Study Comparing Oral MLN9708 plus Lenalidomide and Dexamethasone versus Placebo plus Lenalidomide and Dexamethasone ...
C25003
LYM 84
Randomized, Open Label, Phase 3 Trial of A + AVD versus ABVD as Frontline Therapy in Patients with Advanced Classical Hodgkin Lymphoma
C26002
GI 202
A phase 2 trial of MLN0264 in previously treated patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expr ...
C26003
GI 203
A phase 2 trial of MLN0264 in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C (GCC)
C32496/1105
RM 309
An Open-Label, Phase 1/Phase 2, Single-Agent Study of CEP-32496 in Patients with Advanced Solid Tumors in Phase 1 and in Patients with Advanced Melano ...
CDX011-04
BRE 231
Phase 2 Randomized Study of CDX-011 in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer
CDX011-05
MEL 47
A Phase II Study of Glembatumumab Vedotin, an Anti-gpNMB Antibody-Drug Conjugate, in Patients with Advanced Melanoma
CLEE011E2301
BRE 252
A Phase III randomized, double-blind, placebo-controlled study of LEE011 or placebo in combination with tamoxifen and goserelin or a non-steroidal aro ...
CNS 13
CNS 13
Phase I/II Study of the Combination of BKM120 and Bevacizumab in Patients With Refractory Solid Tumors (Phase I) and Relapsed/Refractory Glioblastoma ...
CO-1686-022
LUN 287
TIGER 1: A Randomized, Open-Label, Phase II Study of CO-1686 or Erlotinib as First-Line Treatment of Patients with EGFR-Mutant Advanced Non-Small Cell ...
CO-338-010
RM 259
A Phase I/II, Open-Label, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Oral Rucaparib in Patients with gBRCA Mutation Breast Cancer or O ...
COMETI-P2-2012.0
BRE 218
Phase 2 study of Characterization of CTCs from subjects with Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
CUDC-907-101
HR 30
Phase I Open Label Multi-center, Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Orally Administered CUDC-907, a PI3 ...
D2270C00005
BRE 196
A Phase I, Open-label, Multicentre, Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD2014 Administered Orally ...
D4191C00001
LUN 282
Phase 3 Randomised, Double-Blind, Placebo-Controlled, Study of MEDI4736 as Sequential Therapy in Patients with Locally Advanced, Unresectable NSCLC wh ...
D4191C0004
LUN 283
A Phase III, Open label, Randomised, Multi-centre, International Study of MEDI4736, versus Standard of Care in Patients with Locally Advanced or Metas ...
DLM-10-001
CNS 14
Open-label, Single Arm, Safety and Tolerability Dose Escalation Study of DAG in Patients With Recurrent Malignant Glioma
EMR200637-002
GI 197
Open Label, Randomized Phase 2 Trial Investigating Two Sym004 Doses versus Investigators Choice in Metastatic Colorectal Cancer and Acquired Resistanc ...
GI 194
GI 194
A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY OF nab®-PACLITAXEL PLUS GEMCITABINE VERSUS GEMCITABINE ALONE AS ADJUVANT THERAPY IN SUBJECTS WITH ...
GO27802
BRE 220
A PHASE Ib OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOLOGY OF GDC-0032 IN COMBINATION WITH EITHER DOCETAXEL OR PACLITAXEL IN PATIENTS ...
GO27826
MEL 30
Phase III, Randomized, Double-Blind Placebo-Controlled study of Vemurafenib Adjuvant Therapy in Surgically Resected, Cutaneous BRAF-Mutant Melanoma at ...
GS-US-313-0124
LYM 85
A Phase 3, Randomized, Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination with Rituximab for Previously Treated I ...
GS-US-339-0102
LYM 89
A Phase 2 Open Label, Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Patients with Relapsed or Refractory Hem ...
GU 111
GU 111
A Phase II Trial to Evaluate the Efficacy of Volitinib in Patients with Previously Treated Papillary Renal Cell Carcinoma (PRCC)
GU 117
GU 117
An Open-Label, Single-Arm, Phase 2 Study of Mocetinostat in Selected Patients with Inactivating Alterations of Acetyltransferase Genes in Previously T ...
GU 99
GU 99
Enzalutamide plus Everolimus in Metastatic Castrate-Resistant Prostate Cancer: Phase 1 Study with a Maximum Tolerated Dose Expansion Cohort
HR 34
HR 34
An Open-label, Phase 1 Study of Bendamustine (B), Rituximab (R) or BR in Combination with IPI-145 in Subjects With Select Relapsed or Refractory Hemat ...
HR 35
HR 35
A PHASE I OPEN-LABEL, MULTI-DOSE, DOSE ESCALATION STUDY OF PRT062070 IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
I3Y-MC-JPBL
BRE 248
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant with or without LY2835219, a CDK4/6 Inhibitor, for Women with Hormone Rec ...
I4T-MC-JVCU
GI 208
Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Capecitabine and Cisplatin with or without Ramucirumab as First-Line Therapy in Patients ...
I6A-MC-CBBD
GU 115
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Me ...
INCB 18424-267
GI 198
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorect ...
INCB18424-268
BRE 242
Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination with Capecitabine in Subjects with Advanced or Metastatic Her2-Negati ...
INCB18424-363
GI 199
Phase 3 Randomized, Double-Blind Study of the JAK1/2 Inhibitor Ruxolitinib or Placebo in Combination with Capecitabine in Advanced or Metastatic Adeno ...
IPI-145-06
LYM 87
A Phase 2 Study of IPI-145 in Subjects with Refractory Indolent Non-Hodgkin Lymphoma
IPI-145-07
CLL30
Phase 3 Study of IPI-145 versus Ofatumumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
IPI-145-12
CLL 31
Study of IPI-145 and Ofatumumab in Patients with CLL/SLL Previously Enroll in IPI-145-07
LUN 214
LUN 214
Phase II Trial of Erlotinib and BKM120 in Patients with Advanced NSCLC Previously Sensitive to Erlotinib
LYM 82
LYM 82
A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of Pinatuzumab Vedotin (DCDT2980S) in Combination With Rituxi ...
LYM 98
LYM 98
A Multi-center Phase I/Ib Study Evaluating the Efficacy and Safety of Brentuximab Vedotin in Combination with TGR-1202, a Novel PI3K Delta Inhibitor, ...
M14-011
BRE 238
Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating Safety and Efficacy of the Addition of Veliparib plus Carboplatin versus the Ad ...
MEL 41
MEL 41
A PHASE Ib, OPEN-LABEL STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED IN COMBINATION WITH VEMURAFENIB IN PATIENTS WITH PREVIOUSLY UNTR ...
ML28257
BRE 208
ML28257/BRE208 An Observational Study of Treatment Patterns and Outcomes in Patients with Her2 Positive Metastatic Breast Cancer
ML28897
PRO 02
Phase 2A Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib, and Vismodegib in Patients who have Advanced Solid Tumors with Mutations or ...
MM 45
MM 45
A Multicenter, Randomized, Open-Label Non-comparative Phase 2 Study of Carfilzomib With or Without ARRY-520 in Patients with Relapsed and Refractory M ...
MM-302-02-02-03
BRE 249
Phase II, Randomized, Open-Label Study of MM-302 plus Trastuzumab vs. Chemotherapy of Physicians Choice plus Trastuzumab in Anthracycline Naïve Patien ...
PAC326
MPN 06
Phase 3 Study of Oral Pacritinib versus Best Available Therapy in Patients with Thrombocytopenia and Primary Myelofibrosis, Post-PV Myelofibrosis, or ...
PAM4983g
RM 245
A PHASE Ib, OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOLOGY OF GDC-0068 IN COMBINATION WITH DOCETAXEL, FLUOROPYRIMIDINE PLUS OXALIPLA ...
PCYC-1130-CA
CLL 34
A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton’s Tyrosine Kinase Inhibitor Ibrutinib in Combination with Obinutuzumab versus Chlor ...
PMT4979g
RM 275
An Open-Label, Phase I, Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Patients with Locally Advanced or Metastatic Solid ...
PPHM1202
LUN 264
Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of Bavituximab plus Docetaxel versus Docetaxel Alone as Second-Line Therapy in Stage IIIB/ ...
PR-30-5010-C
BRE 236
Phase 3, Randomized Trial of Niraparib versus Physicians Choice in Previously Treated Her2 Negative, BRCA Positive Breast Cancer
PR-30-5011-C
GYN 40
A Phase 3 Randomized Double-Blind Trial of Maintenance with Niraparib Versus Placebo in Patients with Platinum Sensitive Ovarian Cancer
RM 294
RM 294
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination with Chemoth ...
RM 312
RM 312
A Phase I, open-label, multiple ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MS ...
RM 316
RM 316
A Phase 1, Open-Label Dose Escalation First-in-Human Study to Evaluate the Tolerability, Safety, Maximum Tolerated Dose, and Pharmacokinetics of AM001 ...
RM 320
RM 320
A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients with Me ...
RM 323
RM 323
A PHASE 1, FIRST-IN-HUMAN STUDY OF ESCALATING DOSES OF ORAL TVB 2640 IN PATIENTS WITH SOLID TUMORS
RM 345
RM 345
A Phase I, Open-Label, Multicentre Dose-Escalation Study to Investigate the Safety and Pharmacokinetics of AZD5312 in Patients with Advanced Solid Tum ...
RM 351
RM 351
A Phase 1b trial of LY2606368 in combination with either cisplatin or cetuximab in advanced or metastatic tumors
RM 355
RM 355
A PHASE 1/2A, MULTICENTER, OPEN-LABEL STUDY OF ORAL RXDX-101 IN ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC CANCER CONFIRMED TO BE POSITIVE FOR ...
RM 376
RM 376
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCB024360 in Combination With MEDI4736 in Subjects With Selected Advanced Solid ...
RM 380
RM 380
A Phase 1, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MLN0128 (an Oral mTORC 1/2 Inhibitor) as a Single Agent and ...
SCRx16-001
LUN 249
Phase I/II Open Label Dose Escalation Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of SC16LD6.5 as a Single Agent in Patients with ...
TGR-1202-101
HR 31
A Phase I Dose Escalation Study Evaluating the Safety and Efficacy of TGR-1202 in Patients with Relapsed or Refractory Hematologic Malignancies
VS-4718-101
RM 307
A Phase I, Open-Label, Dose Escalation Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of VS-4718 in Subjects with Metastatic Non- ...